Dupilumab Biosimilar(Mabpharm)

度普利尤单抗生物类似药（迈博药业）

Report date: 2025/12/26 16:57:35

Base Information

Drug NameDupilumab Biosimilar(Mabpharm)
Drug Alias NameCMAB016CMAB-016
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitorsInterleukin-13 inhibitorsInterleukin-4 inhibitors
TargetsInterleukin-4 receptor subunit alphaInterleukin-13Interleukin-4
Therapy Area/IndicationsPrurigo NodularisDermatitis, AtopicPulmonary Disease, Chronic Obstructive +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMabpharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMabpharm Ltd
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisDermatitis, AtopicPulmonary Disease, Chronic Obstructive +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A